Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

20 Sep 2020

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

NEW YORK, Sept....

By Microdose

Press Releases

17 Sep 2020

COMPASS Pathways announces pricing of upsized initial public offering

Read more on Microdose...

By Microdose

Press Releases

24 Aug 2020

MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

NEW YORK, Aug....

By Microdose

Press Releases

13 Aug 2020

Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results

Reports Strong Cash Position of $24m USD To Execute Multiple Clinical Trials New York, – August 14, 2020 – Mind Medicine (MindMed) Inc....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

5 Aug 2020

MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Applauds Health Canada’s Approval Of Psilocybin Compassionate Access For Patients New York, NY, August 6, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc....

By Microdose

Press Releases

27 Jul 2020

MindMed Completes Dosing 18-MC Phase 1 Study

Company, seeing early success, will advance preparations for Phase 2a clinical trial in opioid addiction New York, NY, July 28, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc....

By Microdose

Press Releases

26 Jun 2020

MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A...

By Microdose

Press Releases

24 Jun 2020

MindMed Developing IP For Personalized Psychedelic Assisted Therapies

MindMed Developing IP For Personalized Psychedelic Assisted Therapies MindMed, in collaboration with the University Hospital Basel, has filed two separate patent applications for technologies to screen and optimize the dosing...

By Microdose

Press Releases

8 Jun 2020

Phase 2 Clinical Trial of LSD for “Suicide Headaches” Begins Treating Patients

Basel, Switzerland, June 8, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.